India defers trade talks on EU drug ban; Hedge funder pushes Baxter for board seats, new CEO;

@FiercePharma: ICYMI yesterday: FDA updates label for Novartis' MS pill Gilenya after reports of brain infection. Article | Follow @FiercePharma

@EricPFierce: Aprecia is building $25M plant where it will do 3D printing of drugs. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Perrigo CEO: Think Mylan's buyout will come easily? Think again. More | Follow @CarlyHFierce

> India has put off free trade talks with Europe after the European Union refused to lift a ban on the sale of about 700 drugs. Report

> Billionaire hedge funder Daniel Loeb asked for two seats on the board of Baxter International ($BAX), saying he could help find a new CEO for the company. Report

> The rate of cancer survival is improving in England, but still lags other countries with similar healthcare systems. Report

> England's cost-effectiveness watchdog said it might consider making AstraZeneca's ($AZN) new drug Lynparza available to ovarian cancer patients who have already undergone three rounds of chemo. Report

Medical Device News

@FierceMedDev: DNAnexus teams up with FDA for Precision Medicine cloud-based genomics platform. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Intuitive awards grants to support training of its da Vinci robot using virtual reality. Article | Follow @VarunSaxena2

@EmilyWFierce: A little news on CEO compensation. More from the WSJ | Follow @EmilyWFierce

> Global tech organization reveals new system for blood glucose monitoring devices. Story

> Medtronic recalls CoreValve TAVR component due to presence of particulate matter. News

> Miniature surgical robot startup gets $11M to assess feasibility in colon resection. Article

Biotech News

@FierceBiotech: Scripps team finds a drug that fights addiction by eliminating memories. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: What's + PhII data from a small allergy study worth? Aimmune bags $160M IPO as the market continues to embrace bio. Article | Follow @JohnCFierce

@DamianFierce: "IPO (n.): An acronym for 'initial public offering' that neglects to mention the taking." More | Follow @DamianFierce

> Epizyme parts ways with its CEO ahead of big Phase II cancer bet. Item

> Eyeing first profits, Tillman Gerngross's Avitide nabs one last VC round. Report

> AstraZeneca buys a new immuno-oncology weapon in $510M Heptares deal. Article

Vaccines News

> U.K's Prokarium scores $585,000 for oral chlamydia vaccine. Report

> State vaccination laws impact outbreak rates, study finds. Item

> Merck Ebola vaccine posts 100% efficacy in PhIII. More

> Novavax reports PhII success for quadrivalent seasonal flu vax. Story

> CSL completes purchase of Novartis' flu vaccine business. Article

CRO News

> Quintiles' $950M IPO keeps on giving for PE backers. Report

> Icon gets in on the ground floor with a Novartis-backed biotech upstart. More

> Patheon signs up to manufacture Flexion's lead drug. Item

> Parexel returns to growth after a shaky quarter. Story

> INC raises its 2015 expectations after another strong quarter. Article

Pharma Manufacturing News

> India, mad over EU ban on drugs, postpones trade talks. Item

> AMRI's expansion binge pays off for CMO. Story

> FDA warning letter smacks Indian lab for repeated shortcomings. More

> French regulator found 30 cases of mold contamination in biotech plant. Report

> GSK moves foward in Bangalore with new Indian plant. Article

Pharma Asia News

> India defers EU trade talks as ban on GVK-tested drugs rankles. Item

> China-focused Mabtech licenses four mAB candidates to Sorrento. More

> BeiGene receives first China trial approval nod for BGB-283. Story

> GSK rehires former China government affairs director Shi. Report

> AstraZeneca stands out again in China, hails AZD9291 in Japan. Article

And Finally... In offering Actavis financing for its purchase of Allergan ($AGN) last year, Japan's Mizhuo Financial Group illustrated its Wall Street ambitions. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.